2,3,7,8-Tetrachlorodibenzo-p-dioxin and β-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism

Toxicology in Vitro

Volumn 24, Issue 3, 2010, Pages 863-871

  Zordoky, Beshay N M ^a   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

AhR; Cytochrome P450s; H9c2 cells; Heart; Hypertrophy; TCDD

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; ATRIAL NATRIURETIC FACTOR; BETA NAPHTHOFLAVONE; BRAIN NATRIURETIC PEPTIDE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 2E1; CYTOCHROME P450 2J3; CYTOCHROME P450 4A1; CYTOCHROME P450 4F4; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ENLARGEMENT; CONTROLLED STUDY; GENE EXPRESSION; HEART HYPERTROPHY; HEART MUSCLE CELL; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ACTINS; ANTIOXIDANTS; BETA-NAPHTHOFLAVONE; CELL LINE; CELL SIZE; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; DNA, COMPLEMENTARY; ENVIRONMENTAL POLLUTANTS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; ISOENZYMES; PROTEIN FOLDING; REACTIVE OXYGEN SPECIES; RECEPTORS, ARYL HYDROCARBON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STILBENES; TETRACHLORODIBENZODIOXIN;

EID: 77649184815     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.12.002     Document Type: Article

References (55)

1. Aboutabl M.E., and El-Kadi A.O. Constitutive expression and inducibility of CYP1A1 in the H9c2 rat cardiomyoblast cells. Toxicol. in Vitro 21 (2007) 1686-1691
2. Aragon A.C., Goens M.B., Carbett E., and Walker M.K. Perinatal 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure sensitizes offspring to angiotensin II-induced hypertension. Cardiovasc. Toxicol. 8 (2008) 145-154
3. Baldwin S.J., Bramhall J.L., Ashby C.A., Yue L., Murdock P.R., Hood S.R., Ayrton A.D., and Clarke S.E. Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). Drug Metab. Dispos. 34 (2006) 1063-1069
4. Beedanagari S.R., Bebenek I., Bui P., and Hankinson O. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol. Sci. 110 (2009) 61-67
5. Bleicher K.B., Pippert T.R., Glaab W.E., Skopek T.R., Sina J.F., and Umbenhauer D.R. Use of real-time gene-specific polymerase chain reaction to measure RNA expression of three family members of rat cytochrome P450 4A. J. Biochem. Mol. Toxicol. 15 (2001) 133-142
6. Canga L., Paroli L., Blanck T.J., Silver R.B., and Rifkind A.B. 2,3,7,8-Tetrachlorodibenzo-p-dioxin increases cardiac myocyte intracellular calcium and progressively impairs ventricular contractile responses to isoproterenol and to calcium in chick embryo hearts. Mol. Pharmacol. 44 (1993) 1142-1151
7. Cao Z., and Li Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur. J. Pharmacol. 489 (2004) 39-48
8. Chabova V.C., Kramer H.J., Vaneckova I., Vernerova Z., Eis V., Tesar V., Skaroupkova P., Thumova M., Schejbalova S., Huskova Z., Vanourkova Z., Kolsky A., Imig J.D., and Cervenka L. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vasc. Pharmacol. 47 (2007) 145-159
9. Chan A.Y., Dolinsky V.W., Soltys C.L., Viollet B., Baksh S., Light P.E., and Dyck J.R. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J. Biol. Chem. 283 (2008) 24194-24201
10. Chen C.J., Yu W., Fu Y.C., Wang X., Li J.L., and Wang W. Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem. Biophys. Res. Commun. 378 (2009) 389-393
11. Chen Q.M., Tu V.C., Wu Y., and Bahl J.J. Hydrogen peroxide dose dependent induction of cell death or hypertrophy in cardiomyocytes. Arch. Biochem. Biophys. 373 (2000) 242-248
12. Choudhary D., Jansson I., Stoilov I., Sarfarazi M., and Schenkman J.B. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab. Dispos. 32 (2004) 840-847
13. Chu C.H., Tzang B.S., Chen L.M., Kuo C.H., Cheng Y.C., Chen L.Y., Tsai F.J., Tsai C.H., Kuo W.W., and Huang C.Y. IGF-II/mannose-6-phosphate receptor signaling induced cell hypertrophy and atrial natriuretic peptide/BNP expression via Galphaq interaction and protein kinase C-alpha/CaMKII activation in H9c2 cardiomyoblast cells. J. Endocrinol. 197 (2008) 381-390
14. Ding Y.S., Trommel J.S., Yan X.J., Ashley D., and Watson C.H. Determination of 14 polycyclic aromatic hydrocarbons in mainstream smoke from domestic cigarettes. Environ. Sci. Technol. 39 (2005) 471-478
15. Dolinsky V.W., Chan A.Y., Robillard Frayne I., Light P.E., Des Rosiers C., and Dyck J.R. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 119 (2009) 1643-1652
16. Dolwick K.M., Swanson H.I., and Bradfield C.A. In vitro analysis of Ah receptor domains involved in ligand-activated DNA recognition. Proc. Natl. Acad. Sci. USA 90 (1993) 8566-8570
17. Elbekai R.H., and El-Kadi A.O. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol. Ther. 112 (2006) 564-587
18. Elbekai R.H., Korashy H.M., Wills K., Gharavi N., and El-Kadi A.O. Benzo[a]pyrene, 3-methylcholanthrene and beta-naphthoflavone induce oxidative stress in hepatoma hepa 1c1c7 cells by an AHR-dependent pathway. Free Radical Res. 38 (2004) 1191-1200
19. Heid S.E., Walker M.K., and Swanson H.I. Correlation of cardiotoxicity mediated by halogenated aromatic hydrocarbons to aryl hydrocarbon receptor activation. Toxicol. Sci. 61 (2001) 187-196
20. Hirasawa F., Kawagoe M., Arany S., Koizumi Y., Ueno Y., and Sugiyama T. Styrene monomer primarily induces CYP2B1 mRNA in rat liver. Xenobiotica 35 (2005) 1089-1099
21. Huang T.H., He L., Qin Q., Yang Q., Peng G., Harada M., Qi Y., Yamahara J., Roufogalis B.D., and Li Y. Salacia oblonga root decreases cardiac hypertrophy in Zucker diabetic fatty rats: inhibition of cardiac expression of angiotensin II type 1 receptor. Diabetes Obes. Metab. 10 (2008) 574-585
22. Kalsotra A., Anakk S., Boehme C.L., and Strobel H.W. Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. Drug Metab. Dispos. 30 (2002) 1022-1028
23. Kanzawa N., Kondo M., Okushima T., Yamaguchi M., Temmei Y., Honda M., and Tsuchiya T. Biochemical and molecular biological analysis of different responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin in chick embryo heart and liver. Arch. Biochem. Biophys. 427 (2004) 58-67
24. Kimes B.W., and Brandt B.L. Properties of a clonal muscle cell line from rat heart. Exp. Cell Res. 98 (1976) 367-381
25. Kopf P.G., Huwe J.K., and Walker M.K. Hypertension, cardiac hypertrophy, and impaired vascular relaxation induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin are associated with increased superoxide. Cardiovasc. Toxicol. 8 (2008) 181-193
26. Korashy H.M., and El-Kadi A.O. Differential effects of mercury, lead and copper on the constitutive and inducible expression of aryl hydrocarbon receptor (AHR)-regulated genes in cultured hepatoma Hepa 1c1c7 cells. Toxicology 201 (2004) 153-172
27. Korashy H.M., and El-Kadi A.O. The role of aryl hydrocarbon receptor and the reactive oxygen species in the modulation of glutathione transferase by heavy metals in murine hepatoma cell lines. Chem. Biol. Interact. 162 (2006) 237-248
28. Korashy H.M., and El-Kadi A.O. The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases. Drug Metab. Rev. 38 (2006) 411-450
29. Kroetz D.L., and Zeldin D.C. Cytochrome P450 pathways of arachidonic acid metabolism. Curr. Opin. Lipidol. 13 (2002) 273-283
30. Laethem R.M., Balazy M., Falck J.R., Laethem C.L., and Koop D.R. Formation of 19(S)-, 19(R)-, and 18(R)-hydroxyeicosatetraenoic acids by alcohol-inducible cytochrome P450 2E1. J. Biol. Chem. 268 (1993) 12912-12918
31. Liu C.J., Cheng Y.C., Lee K.W., Hsu H.H., Chu C.H., Tsai F.J., Tsai C.H., Chu C.Y., Liu J.Y., Kuo W.W., and Huang C.Y. Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells. Mol. Cell. Biochem. 313 (2008) 167-178
32. Magga J., Vuolteenaho O., Tokola H., Marttila M., and Ruskoaho H. B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann. Med. 30 Suppl. 1 (1998) 39-45
33. Masson S., Arosio B., Luvara G., Gagliano N., Fiordaliso F., Santambrogio D., Vergani C., Latini R., and Annoni G. Remodelling of cardiac extracellular matrix during beta-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. J. Mol. Cell. Cardiol. 30 (1998) 1505-1514
34. Mehrabi M.R., Steiner G.E., Dellinger C., Kofler A., Schaufler K., Tamaddon F., Plesch K., Ekmekcioglu C., Maurer G., Glogar H.D., and Thalhammer T. The arylhydrocarbon receptor (AhR), but not the AhR-nuclear translocator (ARNT), is increased in hearts of patients with cardiomyopathy. Virchows Arch. 441 (2002) 481-489
35. Merten K.E., Jiang Y., Feng W., and Kang Y.J. Calcineurin activation is not necessary for Doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway. J. Pharmacol. Exp. Ther. 319 (2006) 934-940
36. Reichard J.F., Dalton T.P., Shertzer H.G., and Puga A. Induction of oxidative stress responses by dioxin and other ligands of the aryl hydrocarbon receptor. Dose-Response 3 (2005) 306-331
37. Rifkind A.B. CYP1A in TCDD toxicity and in physiology-with particular reference to CYP dependent arachidonic acid metabolism and other endogenous substrates. Drug Metab. Rev. 38 (2006) 291-335
38. Rollin R., Mediero A., Fernandez-Cruz A., and Fernandez-Durango R. Downregulation of the atrial natriuretic peptide/natriuretic peptide receptor-C system in the early stages of diabetic retinopathy in the rat. Mol. Vis. 11 (2005) 216-224
39. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82 (2002) 131-185
40. Schwarz D., Kisselev P., Ericksen S.S., Szklarz G.D., Chernogolov A., Honeck H., Schunck W.H., and Roots I. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R), 18(S)-epoxyeicosatetraenoic acid. Biochem. Pharmacol. 67 (2004) 1445-1457
41. Sidorik L., Kyyamova R., Bobyk V., Kapustian L., Rozhko O., Vigontina O., Ryabenko D., Danko I., Maksymchuk O., Kovalenko V.N., Filonenko V.V., and Chaschin N.A. Molecular chaperone, HSP60, and cytochrome P450 2E1 co-expression in dilated cardiomyopathy. Cell Biol. Int. 29 (2005) 51-55
42. Sinal C.J., Webb C.D., and Bend J.R. Differential in vivo effects of alpha-naphthoflavone and beta-naphthoflavone on CYP1A1 and CYP2E1 in rat liver, lung, heart, and kidney. J. Biochem. Mol. Toxicol. 13 (1999) 29-40
43. Sul D., Kim H.S., Cho E.K., Lee M., Kim H.S., Jung W.W., Hwang K.W., and Park S.Y. 2,3,7,8-TCDD neurotoxicity in neuroblastoma cells is caused by increased oxidative stress, intracellular calcium levels, and tau phosphorylation. Toxicology 255 (2009) 65-71
44. Takimoto E., and Kass D.A. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49 (2007) 241-248
45. Thum T., and Borlak J. Gene expression in distinct regions of the heart. Lancet 355 (2000) 979-983
46. Thum T., and Borlak J. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J. 16 (2002) 1537-1549
47. Upadhyay G., Singh A.K., Kumar A., Prakash O., and Singh M.P. Resveratrol modulates pyrogallol-induced changes in hepatic toxicity markers, xenobiotic metabolizing enzymes and oxidative stress. Eur. J. Pharmacol. 596 (2008) 146-152
48. Walker M.K., and Catron T.F. Characterization of cardiotoxicity induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related chemicals during early chick embryo development. Toxicol. Appl. Pharmacol. 167 (2000) 210-221
49. Walker M.K., Pollenz R.S., and Smith S.M. Expression of the aryl hydrocarbon receptor (AhR) and AhR nuclear translocator during chick cardiogenesis is consistent with 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced heart defects. Toxicol. Appl. Pharmacol. 143 (1997) 407-419
50. Wang S., Hartley D.P., Ciccotto S.L., Vincent S.H., Franklin R.B., and Kim M.S. Induction of hepatic phase II drug-metabolizing enzymes by 1,7-phenanthroline in rats is accompanied by induction of MRP3. Drug Metab. Dispos. 31 (2003) 773-775
51. Wu S., Moomaw C.R., Tomer K.B., Falck J.R., and Zeldin D.C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 271 (1996) 3460-3468
52. Zordoky B.N., Aboutabl M.E., and El-Kadi A.O. Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. Drug Metab. Dispos. 36 (2008) 2277-2286
53. Zordoky B.N., and El-Kadi A.O. H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J. Pharmacol. Toxicol. Methods 56 (2007) 317-322
54. Zordoky B.N., and El-Kadi A.O. Induction of several cytochrome P450 genes by doxorubicin in H9c2 cells. Vasc. Pharmacol. 49 (2008) 166-172
55. Zordoky B.N., and El-Kadi A.O. Modulation of cardiac and hepatic cytochrome p450 enzymes during heart failure. Curr. Drug Metab. 9 (2008) 122-128